Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion

Kasr El Aini Hospital40 enrolled

Overview

To assess the levels of TNF- α in vitreous samples of patients with retinal vein occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in vitreous samples of normal subjects so as to investigate the association of vitreous tumor necrosis factor with the pathogenesis of retinal vein occlusion.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Retinal Vein Occlusion

Interventions

measurement of vitreous level of tumor necrosis factor alphaDIAGNOSTIC_TEST

measurement of vitreous level of tumor necrosis factor alpha using ELISA technique

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Any patient with retinal vein occlusion not older than 6 months with no history of Anti-VEGF injection Exclusion Criteria: 1. Diabetic patients. 2. Other causes of retinal vascular diseases. 3. Patients with history of treatment of retinal vein occlusion. 4. Previous intraocular surgery except cataract surgery performed 6 months before the study. 5. Subjects with severe systemic inflammatory diseases 6. Retinal vein occlusion secondary to retinal vasculitis. 7. All retinal pathologies. 8. Patients receiving Systemic steroids or Immunosuppressive therapy.

Locations (1)

Kasr ALainy University hospital

Cairo, Egypt

Outcomes

Primary Outcomes

to assess vitreous level of tumor necrosis factor alpha in retinal vein occlusion and compare it to patient undergoing cataract surgery

Time frame: Day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.